• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Gelesis to Report Third Quarter 2022 Financial Results on November 14, 2022

    11/7/22 7:00:00 AM ET
    $GLS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GLS alert in real time by email

    Gelesis Holdings, Inc. (NYSE:GLS) ("Gelesis" or the "Company"), the maker of Plenity® for weight management, today announced that the Company will report financial results for the third quarter ended September 30, 2022, on November 14, 2022 prior to the market open. Gelesis management will host a live conference call and webcast at 8:30 a.m. ET on the same day to discuss the results.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221107005166/en/

    Gelesis is a consumer-centered biotherapeutics company and the maker of Plenity for weight management. (Photo: Business Wire)

    Gelesis is a consumer-centered biotherapeutics company and the maker of Plenity for weight management. (Photo: Business Wire)

    The live call can be accessed via webcast on the "Events & Presentations" section of the Gelesis Investor Relations website at https://ir.gelesis.com/. The webcast will also be archived and available for replay shortly after the call has concluded. Those who are interested in participating in the live call can dial 844-200-6205 from the U.S. and 929-526-1599 internationally, and enter the access code 849038.

    About Gelesis

    Gelesis Holdings Inc. (NYSE:GLS) ("Gelesis") is a consumer-centered biotherapeutics company and the maker of Plenity®, which is inspired by nature and FDA cleared to aid in weight management. Our first-of-their-kind non-systemic superabsorbent hydrogels are made entirely from naturally derived building blocks. They are inspired by the composition and mechanical properties of raw vegetables, taken by capsule, and act locally in the digestive system, so people feel satisfied with smaller portions. Our portfolio includes Plenity® and potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation. For more information, visit gelesis.com, or connect with us on Twitter @GelesisInc. Plenity® is indicated to aid weight management in adults with excess weight or obesity, a Body Mass Index (BMI) of 25–40 kg/m², when used in conjunction with diet and exercise.

    Important Safety Information about Plenity

    • Patients who are pregnant or are allergic to cellulose, citric acid, sodium stearyl fumarate, gelatin, or titanium dioxide should not take Plenity.
    • To avoid impact on the absorption of medications:
      • For all medications that should be taken with food, take them after starting a meal.
      • For all medications that should be taken without food (on an empty stomach), continue taking on an empty stomach or as recommended by your physician.
    • The overall incidence of side effects with Plenity was no different than placebo. The most common side effects were diarrhea, distended abdomen, infrequent bowel movements, and flatulence.
    • Contact a doctor right away if problems occur. If you have a severe allergic reaction, severe stomach pain, or severe diarrhea, stop using Plenity until you can speak to your doctor.

    Rx Only. For the safe and proper use of Plenity or more information, talk to a healthcare professional, read the Patient Instructions for Use, or call 1-844-PLENITY.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20221107005166/en/

    Get the next $GLS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GLS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GLS
    SEC Filings

    See more
    • Gelesis Holdings Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Leadership Update, Financial Statements and Exhibits

      8-K - GELESIS HOLDINGS, INC. (0001805087) (Filer)

      10/30/23 8:58:39 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form CT ORDER filed by Gelesis Holdings Inc.

      CT ORDER - GELESIS HOLDINGS, INC. (0001805087) (Filer)

      10/19/23 2:14:03 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gelesis Holdings Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - GELESIS HOLDINGS, INC. (0001805087) (Filer)

      10/16/23 4:15:09 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GLS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer

      MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces the appointment of Alison "Ali" Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023. "I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive towards profitable growth. Ali is an exceptionally talented professional with a proven track record of leading a rapidly growing medtech organization through multiple phases of growth. Her experience and talent will prov

      4/3/23 4:05:00 PM ET
      $GLS
      $PEAR
      $SGHT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Computer Software: Prepackaged Software
      Technology
    • Gelesis Reports Fourth Quarter and Full Year 2022 Results

       Gelesis has demonstrated strong demand for Plenity, helping over 200,000 people on their weight loss journeys since launch Company has filed with FDA to make Plenity available to Over the Counter (OTC), which should significantly broaden consumer access and reduce the cost to reach new members Gelesis Holdings, Inc. (NYSE:GLS) ("Gelesis" or the "Company"), the maker of Plenity for weight management, today reported financial results for the year ended December 31, 2022. Plenity is a novel orally administered, FDA-cleared weight management therapy that helps people feel satisfied with smaller portions, so they can eat less and lose weight, while still enjoying the foods they love. Plenity

      3/28/23 7:00:00 AM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gelesis to Participate in the 25th Annual ICR Conference

      Gelesis (NYSE:GLS), the maker of Plenity for weight management, today announced that the Company will participate in the 25th Annual ICR Conference in Orlando, Florida on Monday, January 9, 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230105005182/en/Gelesis is the maker of Plenity, an FDA-cleared weight management product. (Graphic: Business Wire) Gelesis will host a presentation at 1:30 p.m. ET. The live webcast can be accessed on the "Events & Presentations" section of the Gelesis Investor Relations website at https://ir.gelesis.com/. The webcast will also be archived and available for replay. About Gelesis Gelesis H

      1/5/23 7:00:00 AM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GLS
    Leadership Updates

    Live Leadership Updates

    See more
    • Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer

      MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces the appointment of Alison "Ali" Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023. "I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive towards profitable growth. Ali is an exceptionally talented professional with a proven track record of leading a rapidly growing medtech organization through multiple phases of growth. Her experience and talent will prov

      4/3/23 4:05:00 PM ET
      $GLS
      $PEAR
      $SGHT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Computer Software: Prepackaged Software
      Technology

    $GLS
    Financials

    Live finance-specific insights

    See more
    • Gelesis Reports Fourth Quarter and Full Year 2022 Results

       Gelesis has demonstrated strong demand for Plenity, helping over 200,000 people on their weight loss journeys since launch Company has filed with FDA to make Plenity available to Over the Counter (OTC), which should significantly broaden consumer access and reduce the cost to reach new members Gelesis Holdings, Inc. (NYSE:GLS) ("Gelesis" or the "Company"), the maker of Plenity for weight management, today reported financial results for the year ended December 31, 2022. Plenity is a novel orally administered, FDA-cleared weight management therapy that helps people feel satisfied with smaller portions, so they can eat less and lose weight, while still enjoying the foods they love. Plenity

      3/28/23 7:00:00 AM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gelesis Reports Third Quarter 2022 Results

      Plenity quarterly product revenue increased 114% year-over-year to $6.4 million, with 23,500 new members and 92,000 units sold in Q3 Quarterly gross profit increased by $2.6 million year-over-year, with gross margin improving from 8% to 44% Company is preparing to submit Plenity for Over the Counter (OTC) status, which would make it available without the need for a prescription and further reduce cost of customer acquisition Gelesis Holdings, Inc. (NYSE:GLS) ("Gelesis" or the "Company"), the maker of Plenity for weight management, today reported financial results for the third quarter of 2022. Plenity is a novel orally administered, FDA-cleared weight management therapy that helps people

      11/14/22 7:00:00 AM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gelesis to Report Third Quarter 2022 Financial Results on November 14, 2022

      Gelesis Holdings, Inc. (NYSE:GLS) ("Gelesis" or the "Company"), the maker of Plenity® for weight management, today announced that the Company will report financial results for the third quarter ended September 30, 2022, on November 14, 2022 prior to the market open. Gelesis management will host a live conference call and webcast at 8:30 a.m. ET on the same day to discuss the results. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221107005166/en/Gelesis is a consumer-centered biotherapeutics company and the maker of Plenity for weight management. (Photo: Business Wire) The live call can be accessed via webcast on the "Events & Pr

      11/7/22 7:00:00 AM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Gelesis Holdings Inc. (Amendment)

      SC 13D/A - GELESIS HOLDINGS, INC. (0001805087) (Subject)

      10/16/23 4:31:26 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Gelesis Holdings Inc. (Amendment)

      SC 13D/A - GELESIS HOLDINGS, INC. (0001805087) (Subject)

      9/21/23 4:30:30 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Gelesis Holdings Inc. (Amendment)

      SC 13D/A - GELESIS HOLDINGS, INC. (0001805087) (Subject)

      6/29/23 4:30:27 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Puretech Health Plc

      4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

      9/21/23 4:30:07 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Puretech Health Plc

      4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

      6/14/23 4:30:15 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Puretech Health Plc

      4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

      5/31/23 5:30:09 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care